Nonnucleoside Inhibitor Binding Affects the Interactions of the Fingers Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase with DNA
暂无分享,去创建一个
Stephen H. Hughes | S. Tuske | S. Hughes | E. Arnold | Steven Tuske | Edward Arnold | Elena N. Peletskaya | Alex A. Kogon | E. Peletskaya | A. Kogon
[1] S. Sharma,et al. Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase. , 1997, Biochemistry.
[2] S. Drake. NNRTIs-a new class of drugs for HIV. , 2000, The Journal of antimicrobial chemotherapy.
[3] Richard T. Walker,et al. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. , 1996, Journal of medicinal chemistry.
[4] Henri Moereels,et al. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors , 1995, Nature Structural Biology.
[5] A. Telesnitsky,et al. Footprint analysis of replicating murine leukemia virus reverse transcriptase. , 1995, Science.
[6] D W Rodgers,et al. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[7] Jianping Ding,et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. , 1994, Journal of molecular biology.
[8] A. D. Clark,et al. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution. , 1998, Journal of molecular biology.
[9] A. D. Clark,et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. , 1996, Journal of molecular biology.
[10] P. Boyer,et al. Cross-Linking of the Fingers Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase to Template-Primer , 2001, Journal of Virology.
[11] M L Lamb,et al. Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor 8-Cl TIBO: contribution of the L100I and Y181C variants to protein stability and biological activity. , 2000, Protein engineering.
[12] A. D. Clark,et al. Crystal structure of HIV‐1 reverse transcriptase in complex with a polypurine tract RNA:DNA , 2001, The EMBO journal.
[13] P. Boyer,et al. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase , 1994, Antimicrobial Agents and Chemotherapy.
[14] D. Stuart,et al. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. , 1995, Structure.
[15] D I Stuart,et al. Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies. , 1999, Journal of medicinal chemistry.
[16] E. Pedersen,et al. Non-Nucleoside Reverse Transcriptase Inhibitors: The NNRTI Boom , 1999, Antiviral chemistry & chemotherapy.
[17] D I Stuart,et al. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. , 1998, Biochemistry.
[18] P. Boyer,et al. Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1 , 1992, Journal of virology.
[19] T. Quinn,et al. Genomic heterogeneity of AIDS retroviral isolates from North America and Zaire. , 1985, Science.
[20] T. Steitz,et al. The structure of HIV‐1 reverse transcriptase complexed with an RNA pseudoknot inhibitor , 1998, The EMBO journal.
[21] R. Goody,et al. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[22] P. Boyer,et al. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[23] T. Steitz,et al. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.
[24] G. Maga,et al. Selective Interaction of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Nonnucleoside Inhibitor Efavirenz and Its Thio-Substituted Analog with Different Enzyme-Substrate Complexes , 2000, Antimicrobial Agents and Chemotherapy.
[25] Yvonne Jones,et al. High resolution structures of HIV-1 RT from four RT–inhibitor complexes , 1995, Nature Structural Biology.
[26] T. Steitz,et al. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[27] D. Stuart,et al. Continuous and discontinuous changes in the unit cell of HIV-1 reverse transcriptase crystals on dehydration. , 1998, Acta crystallographica. Section D, Biological crystallography.
[28] G L Verdine,et al. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. , 1998, Science.
[29] A. D. Clark,et al. Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. , 1996, Structure.
[30] A. D. Clark,et al. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. , 1998, Journal of molecular biology.
[31] J. Chou,et al. Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E. , 1994, Biochemical pharmacology.
[32] D I Stuart,et al. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[33] D I Stuart,et al. Binding of the Second Generation Non-nucleoside Inhibitor S-1153 to HIV-1 Reverse Transcriptase Involves Extensive Main Chain Hydrogen Bonding* , 2000, The Journal of Biological Chemistry.
[34] Jianping Ding,et al. Molecular modeling studies of HIV‐1 reverse transcriptase nonnucleoside inhibitors: Total energy of complexation as a predictor of drug placement and activity , 1995, Protein science : a publication of the Protein Society.
[35] S. Harrison,et al. Trapping of a catalytic HIV reverse transcriptase*template:primer complex through a disulfide bond. , 2000, Chemistry & biology.
[36] S. Sarafianos,et al. Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. , 1999, Chemistry & biology.
[37] K A Johnson,et al. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors , 1995, Science.
[38] A. D. Clark,et al. Crystals of a ternary complex of human immunodeficiency virus type 1 reverse transcriptase with a monoclonal antibody Fab fragment and double-stranded DNA diffract x-rays to 3.5-A resolution. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[39] Jianping Ding,et al. Protein-nucleic acid interactions and DNA conformation in a complex of human immunodeficiency virus type 1 reverse transcriptase with a double-stranded DNA template-primer. , 1997, Biopolymers.
[40] S. Sarafianos,et al. Similarities and differences in the RNase H activities of human immunodeficiency virus type 1 reverse transcriptase and Moloney murine leukemia virus reverse transcriptase. , 1999, Journal of molecular biology.
[41] D I Stuart,et al. Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants. , 1999, Journal of medicinal chemistry.
[42] A. D. Clark,et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.